GRENSSAP

Research Group in Primary Health Services

GRenSSAP is a research group of primary health care services in Catalonia. This group is made up of a team of researchers from IDIAPJGol and Catalan Institute of Health (ICS). Many of its members participated in the redIAPP network from 2006 to 2024. The aim of the group is research and systematic evaluation of general and specific aspects of the development and function of health services and their relationship with factors affecting health. It is involved in two of three IMPacT programs related to the Precision Medicine infrastructure associated with Science and Technology as IMPacT data and IMPact cohort, leading 6 nodes in Catalonia.

The research group's lines are: 1) Evaluation of the use of services, programs and interventions in Primary Care (PC); 2) Treatment/Follow-up of the most prevalent chronic diseases in PC: classification of multimorbidity patterns, implications of multimorbidity in health services, long-covid, fibromyalgia, validation and improvement of existing information systems in PC; 3) To evaluate the safety, efficiency and use of new drugs and vaccines through the use of a common national and international data model; 4) Assess the natural history and determinants of multiple diseases/health problems (e.g., cancer, COVID-19, obesity, mental health, etc.) from real-world data analysis and interpretation.

Group projects

• Utilization and safety of antidementia treatments: a large longitudinal population-based study in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2025. IP: Carlen Reyes Reyes.

• Uso de fármacos, medicina complementaria y vacunación en mujeres y personas embarazadas y lactantes: estudio cualitativo. 2022-2025. IP: Laura Medina Perucha.

• Time trends in prevalence, incideTime trends in prevalence, incidence and survival of cancer in the OHDSI Networknce and survival of cancer. 2024-2026. IP: Talita Duarte Salles.

• Time trends in incidence and prevalence of sexually transmitted infections among migrants in Catalonia: an analysis of primary healthcare records. 2025-2027. IP: Talita Duarte Salles.

• Tec-Ben: Transformacions Laborals, Innovació Tecnològica i Benestar del Personal Sanitari a Catalunya. Fundació Academia Ciencies Mediques de Catalunya I de Balears (L'Acadèmia). 2025-2026. IP: Pere Torán Monserrat.

• Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine. IQVIA Solutions BV. 2022-2025. IP: Talita Duarte Salles.

• Social inequalities in eating disorders. Agència de Salut Pública de Barcelona (ASPB). 2025-2027. IP: Talita Duarte Salles.

• Sobrecarga en cuidadores/as informales de personas atendidas en el domicilio por Atención Primaria durante la pandemia por covid 19: estudio de metodología mixta. 2022-2025. IP: Carolina Lapena Estella.

• Self-controlled case series (SCCS) study of COVID-19 vaccines and myocarditis and pericarditis (GVDN-VAC4EU-Myocarditis). 2022-2025. IP: Felipe Villalobos Martínez.

• Salut emocional, cures i perimenopausa: un estudi qualitatiu i participatiu per a la co-creació d'una guia pel desenvolupament de polítiques públiques a la ciutat de Barcelona. (24S05923-001). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol); Institut Municipal Hisenda BCN - Ajuntament de Barcelona. 2024-2026. IP: Laura Medina Perucha.

• Salud menstrual, salud mental y calidad de vida en España: estudio de métodos mixtos y participativo para la cocreación de una guía basada en evidencia. (PI22/01389). Instituto de Salud Carlos III. 2022-2026. IP: Anna Berenguera Ossó.

• Safety of Paxlovid during pregnancy (C4671037, VAC4EU & SIGMA study). Pfizer, S.A.; Research Triangle Institute (RTI). 2023-2026. IP: Maria Giner Soriano.

• Safety of Paxlovid among patients with moderate or severe hepatic or renal impairment (C4671047, Vac4eu & Sigma study). Pfizer, S.A.; Research Triangle Institute (RTI). 2023-2026. IP: Maria Giner Soriano.

• Regional Research Protocol to evaluate the effectiveness of dengue vaccines and the risk of Vaccine-Associated Enhanced Disease (VAED) in the Americas. American Health Organization/World Health Organization (PAHO/OPS). 2025-2027. IP: Felipe Villalobos Martínez.

• Real-world coverage and effectiveness of COVID-19 vaccines in vulnerable populations living in Catalonia. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Talita Duarte Salles.

• Proyecto validación Lantitaps. 2022-2025. IP: Diana Puente Baliarda.

• Proyecto INSIGNIA. Una iniciativa para mejorar el seguimiento de los pacientes con Enfermedad Pulmonar Obstructiva Crónica. AstraZeneca Farmacéutica Spain, S.A. 2022-2025. IP: Francisco Martín Luján.

• Post-Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID -19) Vaccine. (C4591021). Fondazione Penta ETS. 2021-2025. IP: Felipe Villalobos Martínez.

• Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries. Pfizer, S.A.; Research Triangle Institute (RTI). 2022-2025. IP: Maria Giner Soriano.

• Post-Authorisation Safety Study of AZD1222. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources. Research Triangle Institute (RTI). 2021-2025. IP: Maria Giner Soriano.

• Pipa 2024:Programa Integrat De Promoció De La Vacunació Antigripal Al Cap Sanllehy (2024). ICS - Institut Català de la Salut. 2024-2025. IP: Carolina Lapena Estella.

• Perfil neurocognitiu de la síndrome post covid en persones adultes de Catalunya: estudi amb mètodes mixtes en un cas-control niat (nested) en cohorts. Breu: Aliança ProHEpiC-19 Cognitiu. (SLT021/21/000055). Generalitat Catalunya. 2022-2025. IP: Pere Torán Monserrat.

• Nuevo abordaje de la violencia machista en atención primaria basado en un algoritmo de inteligencia artificial y formación al profesional, con un proceso participativo: Proyecto VIOLETA. (PI24/01132). Instituto de Salud Carlos III. 2025-2027. IP: Carina Aguilar Martín.

• Multimorbilidad en el Sistema Nacional de Salud: Caracterización poblacional e impacto de sus patrones y trayectorias en personas mayores (Proyecto MM-SNS). (PI22/01398). Instituto de Salud Carlos III. 2022-2025. IP: Concepció Violán Fors.

• Millora del cribratge i el diagnòstic clínic de la disfàgia orofaríngia i la malnutrició en ancians a les àrees sanitàries de la ciutat de Mataró mitjançant un sistema expert basat en intel·ligència artificial. 2023-2026. IP: Pere Torán Monserrat.

• Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. University of California, Los Angeles campus (UCLA). 2022-2025. IP: Talita Duarte Salles.

• La salut mental en adolescents i joves de Barcelona des d'una perspectiva de inequitats socials: estudi poblacional i qualitatiu participatiu. (24S05920-001). Institut Municipal Hisenda BCN - Ajuntament de Barcelona. 2024-2026. IP: Constanza Jacques Aviñó.

• La salud mental en adolescente y jóvenes de Cataluña desde una perspectiva de género: estudio poblacional y cualitativo participativo. (PI22/01278). Instituto de Salud Carlos III. 2022-2026. IP: Constanza Jacques Aviñó.

• La salud emocional adolescente desde una perspectiva crítica: foto-elicitación en el Raval. 2023-2025. IP: Constanza Jacques Aviñó.

• Infecció post-vacunal per SARS-CoV2: Estudi de cohort per la caracterització de la resposta immune i desenvolupament d'un model de predicció per establir criteris de revacunació a Catalunya (BreakCOVID). (SLT021/21/000038). Generalitat Catalunya. 2022-2025. IP: Concepció Violán Fors.

• Iimplementación de una prueba diagnóstica para incrementar la eficacia desde atención primaria en la identificación de pacientes con hipolactasia o deficiencia en lactasa intestinal. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

• Hemorràgies majors en pacients tractats amb anticoagulants i interaccions farmacològiques: estudi cas-control amb dades de la història clínica d'Atenció Primària a Catalunya. 2023-2026. IP: Maria Giner Soriano.

• Expresión de PD-L1 y Marcadores Inflamatorios en la Evolución de Infecciones Virales Respiratorias Agudas en Adultos Mayores de 60 Años: Estudio Observacional Prospectivo en Atención Primaria. (CPP2024-011444). Affirma Biotech S.L; Ministerio de Ciencia e Innovación. 2025-2028. IP: Concepció Violán Fors.

• Experiencias y conocimientos de pacientes y profesionales sanitarios sobre la migraña (Estudio PREMI): Estudio Cualitativo. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

• Evaluación del Plan de Salud de Cataluña 2021 - 2025 Bienestar emocional y Obesidad Infantil, desde la perspectiva de Caso. Generalitat Catalunya. 2024-2026. IP: Anna Berenguera Ossó.

• European Non-interventional Post Authorization Safety Study for romosozumab by the EU-ADR Alliance. 2018-2026. IP: Carlen Reyes Reyes.

• Estudi qualitatiu treball sexual a la ciutat de Barcelona. Agència de Salut Pública de Barcelona (ASPB). 2025-2026. IP: Laura Medina Perucha.

• Estudi qualitatiu sobre el procés de diagnòstic i tractament de la síndrome de l'intestí irritable a l'àrea metropolitana de Barcelona. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Pere Torán Monserrat.

• Estudi d'utilització de medicaments pel tractament de la insuficiència cardíaca. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Maria Giner Soriano.

• Estudi descriptiu sobre la migranya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2026. IP: Maria Giner Soriano.

• Estudi de l'impacte de la pandèmia per Sars-CoV-2 en les cobertures vacunals a Catalunya. ICS - Institut Català de la Salut. 2022-2025. IP: Edurne Zabaleta del Olmo.

• Epidemiology and burden of imminent subsequent fractures in postmenopausal women. University of Oxford. 2023-2026. IP: Carlen Reyes Reyes.

• Encuesta sobre preferencias de medicación entre pacientes con y en riesgo de enfermedad cardiovascular aterosclerótica (ECVA) en la UE5. Merck Sharp & Dohme de España, S.A.; Oracle Ibérica, S.R.L. 2025-2028. IP: Carlen Reyes Reyes.

• Effects of Angiotensin-converting enzyme Inhibitors and Angiotensin receptor blockers: protocol for a Spanish cohort study using routinely collected electronic health records with validation against the ONTARGET trial. London School of Hygiene & Tropical Medicine. 2022-2025. IP: Carlen Reyes Reyes.

• Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen. UMC Utrecht (University Medical Center Utrecht). 2022-2025. IP: Felipe Villalobos Martínez.

• Efecte de la Dieta Mediterrània sobre la funció pulmonar en fumadors sense patologia respiratòria prèvia: l'assaig clínic MEDIS-TAR (Mediterranean Diet and Smoking in Tarragona). Col·legi Oficial de Metges de Tarragona. 2023-2026. IP: Francisco Martín Luján.

• Disseny i validació d'un sistema basat en ia-generativa per al suport a l'assistant clínic a l'atenció primària. EAP Sardenya. 2025-2028. IP: Carlen Reyes Reyes.

• Development of new growth curves for children and adolescents in Catalonia. 2023-2026. IP: Talita Duarte Salles.

• Designing and validating a Real-time Adverse Drug reaction Automated Recognition tool for primary care: the RADAR study. Agència de Gestió d'Ajuts Univ i de Recerca (AGAUR). 2024-2027. IP: Carlen Reyes Reyes.

• Desarrollo de un modelo predictivo de falta de adherencia terapéutica en el contexto del proyecto BEAMER. 2023-2026. IP: Maria Giner Soriano.

• DARWIN EU® - Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Suicidality following exposure to doxycycline. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Monitoring prescription of medicines for public health emergencies at risk of shortages. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

• DARWIN EU® - EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the Omicron variant. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Effectiveness of COVID-19 vaccines on severe COVID-19 and post-acute outcomes of SARS-CoV-2 infection. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2026. IP: Talita Duarte Salles.

• DARWIN EU® - DUS in patients with major depressive disorder. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2023-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Age-specific incidence rates of RSV-related disease in Europe. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions. Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2027. IP: Talita Duarte Salles.

• Construcción y validación de un Score predictivo de riesgo de institucionalización, ingresos hospitalarios y mortalidad, en mayores de 65 años con multimorbilidad y fragilidad - Validación SNAC-K (OMOP). 2023-2026. IP: Concepció Violán Fors.

• Comparación de la efectividad de fármacos en primera línea de tratamiento preventivo de la migraña en Atención Primaria: ensayo clínico pragmático. Estudio PREMI. (ICI23/00047). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol); Instituto de Salud Carlos III. 2023-2026. IP: Maria Giner Soriano.

• Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (WP1). European Medicines Agency (EMA). 2021-2025. IP: Felipe Villalobos Martínez.

• Clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273 (ELASOMERAN). Julius Clinical Research B.V. 2023-2025. IP: Felipe Villalobos Martínez.

• Characterisation and risks of long-term COVID-19 outcomes using large real world data. Instituto de Salud Carlos III. 2022-2025. IP: Talita Duarte Salles.

• Caracterització dels equips d'atenció primària de Catalunya i predicció dels ingressos hospitalaris evitables durant el període 2018-2022. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Concepció Violán Fors.

• Bienestar emocional y social en mujeres y personas en la etapa de la perimenopausia Cataluña: un estudio de fotovoz. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2023-2025. IP: Laura Medina Perucha.

• Avaluació de la utilitat i factibilitat d'una intervenció psicoeducativa per prevenir l'impacte psicològic negatiu de la pandèmia COVID19 en professionals sanitaris d'atenció primària. (SLT021/21/000028). Generalitat Catalunya. 2022-2025. IP: Enric Aragonès Benaiges.

• Atlas para la monitorización de los cuidados en Diabetes. Instituto Aragonés de Ciencias de la Salud (IACS). 2025-2028. IP: Anna Berenguera Ossó.

• Atención cenrtrada en la persona y calidad de vida en mujeres con dispareunia. (PIFIISC22/28). Fundación Canaria Instituto de Investigación Sanitaria de Canarias. 2023-2026. IP: Laura Medina Perucha.

• Air pollution in relation to COVID-19 morbidity and mortality: a large population-based cohort study in Catalonia, Spain (COVAIR-CAT). Fundación Privada Instituto de Salud Global Barcelona (ISGlobal). 2022-2025. IP: Talita Duarte Salles.

• Adiposidad durante la vida y riesgo y mortalidad de cáncer: el rol de comorbilidades e intervenciones para pérdida de peso. (PI23/01186). Instituto de Salud Carlos III. 2024-2026. IP: Talita Duarte Salles.

• Adaptació i validació de la "Practice Environment Scale of the Nursing Work Index" al context organitzatiu dels equips d'Atenció Primària de salut i penitenciària de l'Institut Català de la Salut. 2022-2025. IP: Edurne Zabaleta del Olmo.

• A Randomized, Double-Blind, Controlled Trial to Evaluate the Efficacy and Safety of a Combination of Xyloglucan and Gelose in the treatment of acute diarrhea in adults. (XILAPLUS AF). Noventure, S.L. 2025IP: Carlen Reyes Reyes.

• A randomized, double blind, double dummy, parallel group, multicenter clinical trial to evaluate the safety and clinical and microbiologic efficacy of oral fosfomycin calcium in adult women with uUTI. (EfFoCa2021). Laboratorios ERN, S.A. 2022IP: Pere Torán Monserrat.

• TARGET EU - Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks: Rivaroxaban and risk of major gastrointestinal bleeding in elderly patients with non-valvular atrial fibrillation (version 0.3, 10 November 2025). European Medicines Agency (EMA). 2025-2028. IP: Maria Giner Soriano.

• Study protocol for the Teratogenic Drugs Prioritisation (TDP) project combining pre-clinical data with clinical data from ConcePTION data sources (task 7.9). 2024-2026. IP: Maria Giner Soriano.

• Statins use and portal vein thrombosis in patients with cirrhosis in a Primary Care Setting in Catalonia from 2010 to 2023. 2025-2026. IP: Talita Duarte Salles.

• Post-authorisation safety study to evaluate the utilisation and safety of atogepant in patients with migraine and significant cardiovascular and/or cerebrovascular disease in European countries. Abbvie INC; European Medicines Agency (EMA); Pharmo Institute N.V. 2025-2026. IP: Talita Duarte Salles.

• Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe. (C4591052). 2024-2027. IP: Felipe Villalobos Martínez.

• Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID 19) Vaccine. (C4591038). Fondazione Penta ETS. 2022-2025. IP: Felipe Villalobos Martínez.

• Phenotyping and Treatment Patterns in Cluster Headache in Europe: A Multinational, Multidatabase Network Study. Stichting European Health and Data Evidence Network. 2025-2026. IP: Talita Duarte Salles.

• ORION (Ozanimod Real-World Safety - A Post-Authorisation Multinational Long-Term Non-Interventional Study). European Medicines Agency (EMA); Evidera, Inc. (GB660417353). 2025-2028. IP: Maria Giner Soriano.

• Incidencia y asociación entre la exposición a las medicaciones potencialmente inapropiadas de la herramienta STOPPFall y el riesgo de eventos adversos: estudio de cohortes de base poblacional. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2024-2027. IP: Carlen Reyes Reyes.

• Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe. 2024-2026. IP: Talita Duarte Salles.

• Estudio de utilización de medicamentos para el tratamiento de la insuficiencia cardíaca (IDIAP-IC-2025). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

• Estudi d'utilització de medicaments per al tractament de la malaltia pulmonar obstructiva crònica a Catalunya. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2025-2028. IP: Maria Giner Soriano.

• Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe. AbbVie Inc. 2024-2027. IP: Talita Duarte Salles.

• DARWIN EU® - Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications (P3 C1-004). Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Frailty and polypharmacy among adults aged 18 and above with cancer at the time of diagnosis. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Characterising STOPP criteria medication use in people with recurrent falls. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Azathioprine - user characteristics. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics. Erasmus Universitair Medisch Centrum Rotterdam (EMC); European Medicines Agency (EMA). 2024-2027. IP: Talita Duarte Salles.

• DARWIN EU® - Antipsychotic prescribing in Europe: a descriptive analysis of trends and patient characteristics. European Medicines Agency (EMA). 2024-2025. IP: Talita Duarte Salles.

• Characterization of incidental and chronic use of macrolides in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap syndrome (ACOS); a pharmacoepidemiologic drug utilization study with data mapped to the Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM). Erasmus Universitair Medisch Centrum Rotterdam (EMC). 2024-2027. IP: Talita Duarte Salles.

• Atlas de prescripción farmacéutica en Diabetes. Instituto Aragonés de Ciencias de la Salud (IACS). 2025-2028. IP: Anna Berenguera Ossó.

• Asociación entre los niveles de vitamina D en sangre, los suplementos con vitamina D y las fracturas osteoporóticas en la población catalana: estudio de base poblacional. 2024-2027. IP: Carlen Reyes Reyes.

• Antiseizure meDication Exposure and Pregnancy and neonaTal outcomes research (ADEPT). Use of antiepileptics, and feasibility of studies on the association between maternal and paternal exposure to antiepileptics and adverse pregnancy, neonatal and child outcomes. (EMA/453898/2023). European Medicines Agency (EMA). 2024-2027. IP: Maria Giner Soriano.

• A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK. (C3671038). European Medicines Agency (EMA); Pfizer, S.A. 2025-2025. IP: Felipe Villalobos Martínez.

• A Post-Authorisation Safety Study of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK. (C3671026). Pfizer Ltd; Pfizer, S.A. 2025-2028. IP: Felipe Villalobos Martínez.

• A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU: Study protocol for the occurrence of flares of Graves´ disease, Hashimoto´s thyroiditis, polyarteritis nodosa, autoimmune hepatitis, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, erythema nodosum, systemic lupus erythematosus, and ulcerative colitis using electronic healthcare data sources. European Medicines Agency (EMA). 2024-2027. IP: Felipe Villalobos Martínez.

• A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU. Universiteit Utrecht. 2024-2027. IP: Felipe Villalobos Martínez.

• A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data. European Medicines Agency (EMA). 2024-2026. IP: Maria Giner Soriano.

• Revisión sobre cohesión social: evidencia sobre la asociación entre la cohesión social/capital social y la salud, así como del abordaje e implementación de políticas públicas en dicha área. American Health Organization/World Health Organization (PAHO/OPS). 2022-2026. IP: Constanza Jacques Aviñó.

• Multimorbidity and Frailty Trajectories and Explainable Prediction Models for Health-related Outcomes Using Longitudinal Electronic Health Records of the Ageing Catalan Population. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). IP: Lucía Amalia Carrasco Ribelles.

• Mejora en la Integración Fundanet-GIR. (MDG-23-11571). Fundación Española para la Ciencia y la Tecnologia (FECYT). 2023-2025. IP: Anna Moleras Serra.

• La salud mental en adolescente y jóvenes de Cataluña desde una perspectiva de género: estudio poblacional y cualitativo participativo. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). IP: Ana Lozano Sánchez.

• Effectiveness of a motivational intervention based on spirometry results to achieve smoking cessation in primary healthcare patients: randomised, parallel, controlled multicentre study. Col·legi Oficial de Metges de Tarragona. IP: Francisco Martín Luján.

• DARWIN-EU. European Medicines Agency (EMA). 2022IP: Talita Duarte Salles.

• Construcción y validación de un Score predictivo de riesgo de institucionalización, ingresos hospitalarios y mortalidad, en mayores de 65 años con multimorbilidad y fragilidad. (FI20/00040). Instituto de Salud Carlos III. 2020-2025. IP: Lucía Amalia Carrasco Ribelles.

• Enquesta Salut Bucodental. Generalitat Catalunya. 2025-2026. IP: Carina Aguilar Martín.

• Avaluació Pla de Salut Obesitat infantil i Benestar Emociona. Generalitat Catalunya. 2023-2025. IP: Anna Berenguera Ossó.

Group Publications

• Blay N, Carrasco Ribelles LA, Farré X, Iraola Guzmán S, Danés Castells M, Violán C et al. Weighting health-related estimates in the GCAT cohort and the general population of Catalonia. Sci Rep. 2025;15(1):16984-16984. PMID:40374680.

• Carrasco Ribelles LA, Cabrera Bean M, Llanes Jurado J, Violán C. Use of Attention Maps to Enrich Discriminability in Deep Learning Prediction Models Using Longitudinal Data from Electronic Health Records. Appl. Sci.-Basel. 2025;15(1).

• Fernández Garcia S, Moragas A, Giner Soriano M, Morros R, Ouchi D, Garcia Sangenis A et al. Urinary tract infections in women in Catalonia, Spain: a population-based observational cohort study in primary care. Front. Pharmacol. 2025;161593910-1593910. PMID:40994650.

• Medina Perucha L, García Egea A, Jacques Aviño C. Understanding Menstrual Inequity: A Consensus-Based Definition and Comprehensive Exploration. Womens Reprod. Health. 2025.

• Xie JQ, Du MK, Guo YC, Barboza C, Brash JT, Delmestri A et al. Trends in prescription opioid use in Europe: A DARWIN EU® multinational cohort study including seven European countries. Front. Pharmacol. 2025;161608051-1608051. PMID:40900825.

• Cuyàs B, Alvarado Tapias E, Tan EH, Golozar A, Duarte Salles T, Delmestri A et al. Trends in incidence, prevalence, and survival of primary liver cancer in the United Kingdom (2000-2021). Eur. J. Public Health. 2025;36(2):PMID:41212072.

• Santesmases Masana R, Hernández Esparza E, Campillo Zaragoza B, Lapena Estella C, Mañes López E, Checa C et al. Translation and psychometric evaluation of the Spanish version of the Heart Failure-Specific Health Literacy. Patient Educ. Couns. 2025;135108732-108732. PMID:40081156.

• Rostami S, Bermudo Gallaguet A, Camins Vila N, Ferrer Uris B, Busquets A, Ribera M et al. The YoungFitT project: Study protocol for a randomized mixed-methods trial of physical exercise and mind-body interventions, with or without virtual reality, in university students. PLoS One. 2025;20(8):PMID:40748900.

• Luján FM, Alberich RS. The usefulness of studying visceral fat for early stratification of atherogenic risk: from conventional anthropometry to more accurate measurements. Clin. Invest. Arterioscler. 2025;37(6):500874-500874. PMID:41276337.

• Fortuny DB, López SR, Martínez Torres S, Rey Reñones C, Martín Luján FM. The Influence of Virtual Reality Glasses Use on the Quality of Life of Older Adults: Protocol for a Prospective, Longitudinal Quasi-Experimental Study. JMIR RES. Protoc. 2025;14PMID:41432992.

• Alvarez Sierra D, Martínez Gallo M, Sánchez Montalvá A, Fernández Sanmartín M, Colobran R, Espinosa Pereiro J et al. The immune response to SARS-CoV-2 in COVID-19 as a recall response susceptible to immune imprinting: A prospective cohort study. Clin. Immunol. 2025;272110429-110429. PMID:39842683.

• Lopez Jimenez T, Plana Ripoll O, Duarte Salles T, Palomar Cros A, Puente D. The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study. BMC Public Health. 2025;25(1):178-178. PMID:39825260.

• López Contreras N, López Jiménez T, Medina Perucha L, León Gómez BB, Gonçalves AQ, Horna Campos OJ et al. Syndemic, mental health and living with dependent persons in Latin America and Spain: a study with a gender perspective. Arch. PUblic Health. 2025;83(1):24-24. PMID:39863880.

• Zabaleta Olmo E, Rey Renones C, Marchal Torralbo A, Sauch Valmana G, Calvet Tort G, Planas Campmany C et al. Structural Validity and Reliability of an Adapted Practice Environment Scale-Nursing Work Index for Primary Health Care Nurses. Res. Nurs. Health. 2025;48(5):533-544. PMID:40464625.

• Busquet Duran X, Moreno Gabriel E, Verdaguer M, Jiménez Zafra EM, Manresa Domínguez JM, Torán Monserrat P. Spiritual Complexity in Palliative Home Care in Spain: A Multi-center Prospective Study. J. Relig. Health. 2025;64(3):2297-2320. PMID:40193022.

• Pedret Llaberia R, Basora Gallisà T, Martínez Torres S, Rodríguez Soler S, Pallejà Millán M, Buscemi A et al. Social and Demographic Determinants of Health: A Descriptive Study on the Impact of Place of Residence and Community Belonging. Healthcare. 2025;13(10): PMID:40427962.

• Capitán Fernández AM, Gutiérrez Vallés V, Luis Pérez C, Cerrillo Borja M, Rodríguez Morales N, Tejedor Bartolomé R et al. Sobrecarga en cuidadores familiares de personas atendidas en el domicilio por Atención Primaria durante la pandemia covid-19: estudio exploratorio. Rev Esp Geriatr Gerontol. 2025;60(5):101656-101656. PMID:40233608.

• Lamonja Vicente N, Dacosta Aguayo R, Lopez Oloriz J, Prades Senovilla L, Soriano Raya JJ, Clemente IC et al. Sex and APOE e2 Interactive Effects on the Longitudinal Change in Cognition in a Population-Based Cohort of Older Adults with Vascular Risk Factors. Int. J. Mol. Sci. 2025;26(21): PMID:41226628.

• Sánchez Recio R, Oliván Blázquez B, Méndez López F, Gascón Santos S, Marti Lluch R, Zabaleta Olmo E et al. Self-reported health and depression among EIRA cohort: a moderated mediation model of sex and perceived social support. Front. Psychol. 2025;161540530-1540530. PMID:40584072.

• Bellas L, Català M, Burn E, Guo YC, Du M, Verhamme K et al. Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study. Pharmacoepidemiol. Drug Saf. 2025;34(10):PMID:41099219.

• Bennett M, López Jiménez T, Medina Perucha L, León Gómez BB, Berenguera A, Jacques Aviñó C. Risk perception and coping mechanisms by gender identity and education level during the COVID-19 syndemic in Spain. BMC Psychol. 2025;13(1):598-598. PMID:40462188.

• Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR et al. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025;48(8):1386-1394. PMID:40465422.

• Nasreen S, Jiang Y, Lu H, Lee A, Cutland CL, Gentile A et al. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study. Vaccine. 2025;60127291-127291. PMID:40440921.

• Bellas L, Camacho Arteaga L, Giner Soriano M, A, Gómez Lumbreras A, Aguilera C et al. Real-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain). Drug Saf. 2025;48(12):1353-1364. PMID:40632487.

• Leceaga Gaztambide E, Domingo M, Manresa JM, Conangla Ferrin L, Alpiste M, Juviña M et al. Rationale and design of a prospective study evaluating the prognostic value of lung ultrasound in patients with heart failure in primary care: the EPICAP study protocol. BMC Prim. Care. 2025;26(1):410-410. PMID:41291478.

• Bee Nchama M, Manzano J, Pajunen MG, Zhang Yim JI, González Rábago Y, Jacques Aviñó C et al. Racismo: el determinante social de la salud invisibilizado en España. Rev. Esp. Salud Publica. 2025;99PMID:41200953.

• Nchama MB, Yim J, Jacques Aviño C, Manzano J, González Rábago Y, La Parra Casado D et al. Racism: the invisible social determinant of health in Spain. Rev. Esp. Salud Publica. 2025;99.

• Lopez Dicastillo O, Iriarte Roteta A, Antoñanzas Baztán E, Sola Cia S, Mujika A, Hernantes N et al. PromoACTIVA-SC: A Tool Aiming at Identifying Health Promotion Practice of Civil Society Organizations. Healthcare. 2025;13(17):PMID:40941450.

• León Gómez BB, Carmona Cervelló M, Dacosta Aguayo R, Lamonja Vicente N, Bielsa Pascual J, López Lifante VM et al. Prevalence and severity of anxiety, stress, and depression in long COVID among adults in Barcelona. BJGP Open. 2025;9(3):PMID:39848702.

• Gallego Moll C, Carrasco Ribelles LA, Casajuana M, Maynou L, Arocena P, Violán C et al. Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review. Value Health. 2026;29(1):159-171. PMID:40848744.

• Zabaleta Olmo E, Reñé A, Sauch Valmaña G, Rios Jiménez A, Marchal Torralbo A, Rey Reñones C et al. Practice Environment Scale-Nursing Work Index for use in primary health care: a qualitative content validity study. RqR Enferm. Comunitaria. 2025;13(3).

• Hernández Rojas Z, Dalmau Llorca MR, Aguilar Martín C, Castro Blanco E, García Goñi M, Alegret JM. Population-based analysis of the cost of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation. Rev. Esp. Cardiol. 2025;78(7):652-655. PMID:40097002.

• Marzo Castillejo M, Mascort Roca J, Brau Tarrida A, Carrasco Ribelles L, Monteagudo Zaragoza M, Guiriguet Capdevila C et al. Participant selection for lung cancer screening using primary care electronic medical records: The Catalan scenario. Aten. Prim. 2026;58(1):103363-103363. PMID:41260054.

• Feijoo Cid M, Verdaguer M, Busquet Duran X, Moreno Gabriel E, Domènech M, Iñiguez Rueda L et al. Nursing care in assisted dying: Plasticity and relational commitment. Nurs. Ethics. 2025;32(7):2044-2058. PMID:40235214.

• Estarlich Corominas J, Soler Abril N, Casanellas Chuecos A, Becerra Corzo S, Bianco AS, Torán Monserrat P et al. Nurse management of minor problems in primary care emergencies: a non-randomized controlled trial. BMC Nurs. 2025;24(1):87-87. PMID:39856650.

• Céspedes AA, Molina RG, Córcoles RA, Saro AA, Ramírez MM, Merchante IM et al. Multicenter randomized clinical trial to analyze the efficay of the Spanish National Healthcare System intervention to reduce frailty status in prefrail or frail older adults (FRAILMERIT). Study protocol. Rev. Esp. Salud Publica. 2025;99.

• García Egea A, Pujolar Díaz G, Hüttel AB, Holst AS, Jacques Aviñó C, Medina Perucha L. Mapping the health outcomes of menstrual inequity: a comprehensive scoping review. Reprod. Health. 2025;22(1):156-156. PMID:40898260.

• Pera V, Lepouttre H, Barboza C, Palomar Cros A, López Sánchez I, Duarte Salles T et al. Macrolide prescribing and preemptive electrocardiograms in asthma, COPD, ACO, and general population: a drug-utilization study. J. Asthma. 2026;63(2):1-14. PMID:41250618.

• Redondo JM, Comas C, Pons MC, Serrano CG, Salud JP, Closas MC et al. Lung ultrasound is cost-effective for early diagnosis of COVID-19 pneumonia in primary care. BMC Pulm. Med. 2025;25(1):300-300. PMID:40604586.

• Ginès P, Guha IN, Fabrellas N, Allen AM, Angeli P, Serra Burriel M et al. Liver Health: An Emerging Concept. Gastroenterology. PMID:39909131.

• Alòs F, Puig Ribera A, Bort Roig J, Chirveches Pérez E, Berenguera A, Martin Cantera C et al. Incorporating sedentary behaviour for identifying risk of type 2 diabetes: Implications for primary care. Prim. Care Diabetes. 2025;19(3):214-220. PMID:40068985.

• Aragonès E, Lozano Sánchez A, López Jiménez T, Bennett M, Evangelidou S, Francisco E et al. Incidence trends and clinical management of self-harm in adolescents and young adults in catalonia: primary care cohort study (2013-2022). Eur. Child Adolesc. Psych. 2025;35(2):437-448. PMID:40884581.

• Pedregal Pascual P, Guarner Argente C, Tan EH, Golozar A, Duarte Salles T, Rosen AW et al. Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study. Am. J. Gastroenterol. 2025;120(12):2909-2917. PMID:40167184.

• Toledo D, Cartanyà Hueso À, Morros R, Giner Soriano M, Domínguez À, Vilaplana Carnerero C et al. Impact of Long-Term Statin Therapy on Incidence and Severity of Community-Acquired Pneumonia: A Real-World Data Analysis. Biomedicines. 2025;13(6):PMID:40564157.

• Castillo Cano B, Riefolo F, Villalobos F, Martín Pérez M, Messina D, Elbers R et al. Impact and Effectiveness of COVID-19 mRNA Vaccination Against COVID-19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain. Pharmacoepidemiol. Drug Saf. 2025;34(11): PMID:41125425.

• Violán C, Quirant Sánchez B, Palau Antoja M, Palacin D, Pradenas E, Trigueros M et al. Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The Immersion Study. Vaccines. 2025;13(7):PMID:40733715.

• Alayo I, Pujol O, Alonso J, Ferrer M, Amigo F, Diest A et al. Identifying most important predictors for suicidal thoughts and behaviours among healthcare workers active during the Spain COVID-19 pandemic: a machine-learning approach. Epidemiol. Psychiatr. Sci. 2025;34PMID:40340775.

• Yela E, Abiétar DG, Clua García R. How to eliminate hepatitis C between people who inject drugs in community services and prisons in Catalonia. Harm Reduct. J. 2025;22(1):133-133. PMID:40745598.

• Pistillo A, Giuliodori A, Palomar Cros A, Gallo E, Aragonés E, Ballester J et al. High temperature and mental health in 3.3 million adults living in Barcelona metropolitan area: a 12-year time series analysis of primary care data. Environ. Int. 2025;203109748-109748. PMID:40886399.

• Domínguez Armengol G, Ribas Aulinas F, Balló E, Alzamora Sas M, Serrat Costa M, Ruiz Comellas A et al. Health program for prEvention of cardiovascuLar disEases based on a risk screeNing strategy with Ankle-brachial index: HELENA study protocol. Front. Public Health. 2025;131484163-1484163. PMID:40520295.

• Barranco Altirriba M, Granado Casas M, Yanes O, Capellades J, Junza A, Franch Nadal J et al. Guanine and pregnenolone sulfate are associated with incident type 2 diabetes in two independent populations. Front. Endocrinol. 2025;161706886-1706886. PMID:41416067.

• Esteban Fabró R, Coma E, Marin Gomez FX, Hermosilla E, Mendez Boo L, Guiriguet C et al. Financial incentives and information provision for post-pandemic primary care quality recovery: a longitudinal study in Catalonia. Br. J. Gen. Pract. 2026;PMID:41344817.

• Horna Campos O, Gómez N, Mazzei Pimentel M, Anigstein MS, Gongora Jercic G, Cid Vera J et al. Factors associated with the increased consumption of sugary beverages and fast-food during Chile's first COVID-19 lockdown. Medwave. 2025;25(5):PMID:40456140.

• Llor C, Ouchi D, Fernández García S, Giner Soriano M, Moragas A, Morros R. Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study. BMJ Open. 2025;15(8):PMID:40819861.

• Moreno Gabriel E, Bielsa Pascual J, Verdaguer M, Carmona Cervelló M, Lamonja Vicente N, León Gómez BB et al. Experiencias de las personas con sintomatología neuropsicológica de covid persistente en Cataluña: un estudio fenomenológico. Aten. Prim. 2025;57(6):103214-103214. PMID:39854988.

• Abellan A, Burn E, Trinh NTH, Burkard T, Callahan A, Fernández Bertolín S et al. Expanding the OMOP Common Data Model to Support Perinatal Research in Network Studies. Pharmacoepidemiol. Drug Saf. 2025;34(2):PMID:39950235.

• Clua Espuny JL, Hernández Pinilla A, Gentille Lorente D, Muria Subirats E, Forcadell Arenas T, de Diego Cabanes C et al. Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study). Biomedicines. 2025;13(1): PMID:39857703.

• Fiol deRoque MA, Valderas JM, Serrano Ripoll MJ, Gens Barbarà M, Martín Luján F, Sánchez Freire E et al. Evaluating SinergiAPS, an intervention based on patient feedback to improve patient safety in primary care: a cluster randomized trial. BMC Med. 2025;23(1):202-202. PMID:40189506.

• Arteaga I, Chacón C, Martínez Escudé A, Rojano IR, Diez Fadrique G, Carmona Cervelló M et al. Evaluating Pediatric NAFLD with Controlled Attenuation Parameter: A Comprehensive Narrative Review. Diagnostics. 2025;15(3):PMID:39941229.

• Guiriguet C, Bustos M, Cantenys R, Hermosilla E, Camús J, Medina M et al. Enhancing the follow-up for patients with type 2 diabetes mellitus using a proactive scheduling computer tool: A paired cohort study in primary care. Prim. Care Diabetes. 2025;19(3):334-340. PMID:40157873.

• Bermudo Gallaguet A, Ariza M, Agudelo D, Camins Vila N, Boldo M, Peters S et al. Effects of Mindfulness and Exercise on Growth Factors, Inflammation, and Stress Markers in Chronic Stroke: The MindFit Project Randomized Clinical Trial. J. Clin. Med. 2025;14(8):PMID:40283415.

• Bermudo Gallaguet A, Ariza M, Agudelo D, Camins Vila N, Boldó M, Ferrer Uris B et al. Effects of mindfulness and exercise on cognition and emotion in adults with mild deficits in the chronic post-stroke phase: A randomized controlled trial. Ann. Phys. Rehabil. Med. 2025;68(7):102008-102008. PMID:40845631.

• Campabadal Prats C, Aragonès E, Romeu M, Salom Garrigues C, Bejarano F, Luján FM et al. Effectiveness of a structured pharmaceutical review of pharmacotherapeutic plans to reduce drug-related problems in nursing homes: a study protocol of a pragmatic quasi-experimental trial. Front. Pharmacol. 2025;161522650-1522650. PMID:40717969.

• Schillok H, Gensichen J, Panagioti M, Gunn J, Junker L, Lukaschek K et al. Effective Components of Collaborative Care for Depression in Primary Care: An Individual Participant Data Meta-Analysis. JAMA Psychiatry. 2025;82(9):868-876. PMID:40136273.

• Giner Soriano M, Ricart GA, Cartanyà Hueso A, Gomez Lumbreras A, Vázquez ML, Morros R et al. Drug exposure during breastfeeding: a descriptive population-based cohort study with SIDIAP database. Int. Breastfeed. J. 2025;21(1):7-7. PMID:41444905.

• Cabedo Ferreiro R, Reyes Lacalle A, Cos Busquets J, Colldeforns Vidal M, Liutsko L, García Sierra R et al. Does Maternal Diet Vary During the Postpartum Period According to Infant Feeding Type? The Observational Study GREEN MOTHER. Nutrients. 2025;17(7):PMID:40218894.

• Lamonja Vicente N, Tintorer DL, Palau Antoja M, León Gómez BB, Torán Monserrat P. Dietary and Behavioral Interventions for Diabetes: Current Evidence, Challenges, and Opportunities. Nutrients. 2025;17(16):PMID:40871632.

• Carrasco Ribelles LA, Cabrera Bean M, Khalid S, Roso Llorach A, Violan C. Development of Attention-based Prediction Models for All-cause mortality, Home Care Need, and Nursing Home Admission in Ageing Adults in Spain Using Longitudinal Electronic Health Record Data. J. Med. Syst. 2025;49(1):17-17. PMID:39862306.

• Antón Solanas I, Callén Galindo M, Urcola Pardo F, López Dicastillo O, Mujika A, Hernantes N et al. Development and content validation of a questionnaire of activities in health promotion for primary and secondary education: PromoACTIVA-CE. BMC Public Health. 2025;26(1):324-324. PMID:41437015..

• Torres SC, Parra Vargas E, Carrasco Ribelles L, Marín Morales J, Alcaniz M. Detecting inhibition and activation tendencies in organizational behavior: a virtual reality and machine learning-based methodological framework. Curr. Psychol. 2025;44(17):14282-14293.

• Hernández Vidal N, Pujol Vidal M, Mengíbar García Y, Ayala Villuendas D, Contel Segura JC, Martínez Torres S et al. Design, Implementation, and Evaluation of Healthcare Visual Map Tool for Health Workers to Improve Quality of Life of Home Care Patients: Study Protocol. Healthcare. 2025;13(6):PMID:40150476.

• Flamarich Gol C, Feijoo Cid M, Bielsa Pascual J, Almazan Gómez M, Ramos Roure F, Moreno Gabriel E et al. Cultural Competence in the Public Health System: A Cross-Sectional Study in the Northern Metropolitan Area of Barcelona. J. Prim. Care Community Health. 2025;16PMID:41109960.

• Giner Soriano M, Morros R, Monfà R, Ouchi D, Fernández García S, Vedia C et al. Comparison of the effectiveness of first-line preventive treatment of migraine in primary care: study protocol for a pragmatic clinical trial (PREMI study). Trials. 2025;26(1):311-311. PMID:40859286.

• Hernáez A, Camps Vilaró A, Polo Alonso S, Subirana I, Ramos R, de Cid R et al. Cohort profile: the CORDELIA study (Collaborative cOhorts Reassembled Data to study mEchanisms and Longterm Incidence of chronic diseAses). Eur. J. Epidemiol. 2025;40(5):581-599. PMID:40353978.

• Maisonneuve E, Luxi N, Bellitto C, Ciccimarra F, Raethke M, van Hunsel F et al. Cohort event monitoring of booster COVID-19 vaccine safety using patient-reported outcomes in pregnant women. Front Drug Saf Regul. 2025;51689349-1689349. PMID:41532034.

• Agüera Ortiz L, Aragonés E, Buch Vicente B, Mendive JM, Peña M, Vieta E. Cognitive symptoms in schizophrenia: an analysis of awareness, assessment, and management practices among psychiatrists and primary care physicians. Front. Psychiatry. 2025;161567410-1567410. PMID:40405881.

• Gonzalez Rio M, Merchan Ruiz M, Reñé A, Bertran Noguer C, Ramió Torrentà L, Zabaleta Olmo E. Cognitive interviewing study to assess the content validity of a Spanish version of the Multiple Sclerosis Health Literacy Questionnaire. Public Health. 2025;245105761-105761. PMID:40393337.

• López Güell K, Català M, Dedman D, Duarte Salles T, Kolde R, López Blasco R et al. Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries. J. Clin. Epidemiol. 2025;185111867-111867. PMID:40517846.

• García Egea A, García Sangenís A, Llor C, Berenguera A, Moragas A, Monfà R et al. Clinicians' perspectives on a primary healthcare intervention to reduce antibiotic prescription for acute lower respiratory tract infections in Barcelona (Spain): a qualitative study. Prim. Health Care Res. Dev. 2025;26PMID:40611657.

• Dalmau Llorca MR, Hernández Rojas Z, Castro Blanco E, Carrasco Querol N, Gonçalves AQ, Espuny Cid A et al. Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation. J. Clin. Med. 2025;14(3):PMID:39941667.

• Zwiers LC, Grobbee DE, Schneijdenberg R, Baljé C, Laurent STS, Esposito DB et al. Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources. Vaccines. 2025;13(7):PMID:40733732.

• Seguí DR, Forcadell MJ, Vila Córcoles A, De Diego Cabanes C, Ochoa Gondar O, Lujan FM et al. Classification rule for ten year MACE Risk in primary care tarragona older adults with type2 diabetes: a CHAID decision-tree analysis. BMC Prim. Care. 2025;26(1):129-129. PMID:40281435.

• Reyes Lacalle A, Cabedo Ferreiro RM, Cos Busquets J, Liutsko L, Colldeforns Vidal M, García Sierra R et al. Characteristics, Preventive Factors, and Barriers to Breastfeeding and Mixed Feeding in the First Month of Life in Barcelona: The Multicenter Observational Study GREEN MOTHER. Nutrients. 2025;17(19):PMID:41097185.

• Pineda Moncusí M, Rekkas A, Martínez Pérez Á, Leis A, Lopez Gomez C, Fey E et al. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. Lancet Public Health. 2025;10(10): PMID:40992879.

• Motevalizadeh E, Díaz López A, Jardí C, Rey Reñones C, Martín Luján F, Arija V. Cardiometabolic Markers Associated With Altered Fetal Growth in Mediterranean Cohort. Matern. Child Nutr. 2025;21(4):PMID:40767273.

• Minana Castellanos M, Fernández Martín MI, Rodríguez Barragán M, Marques M, Sisó A, Basora J et al. Burnout among Catalan general practitioners. A repeated cross-sectional study, during and after the COVID-19 pandemic. Eur. J. Gen. Pract. 2025;31(1):2485073-2485073. PMID:40208687.

• Gallardo Nuell L, Blanch J, Leal Y, Coral DE, Duarte Salles T, Giordano GN et al. BMI-residualized data uncovers a cluster of people with type 2 diabetes and increased serum ferritin protected from cardiovascular disease. Cardiovasc. Diabetol. 2025;24(1):139-139. PMID:40140920.

• Rullan Rabassa A, Abiétar GD, Rando Matos Y, Ballvé Moreno JL, Daryanani Nawalrai S, Hernández Méndez P et al. Barriers and facilitators to performing benign paroxysmal positional vertigo manoeuvres among primary care physicians in Barcelona: a qualitative study. BMJ Open. 2025;15(12): PMID:41365585.

• Reyes C, Pou MA, Diaz Torne C, Carbonell Abella C, Brotons C, Martinez Laguna D. Association of morphine vs. fentanyl prescription dispensation with adverse clinical outcomes. Front. Pharmacol. 2025;161579634-1579634. PMID:40635750.

• Giner Soriano M, Carrasco Ribelles LA, Fernández García S, Castel Llobet J, Cereza García G, Morros R. Association Between Anticoagulants and Interacting Drugs and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation: Case-Control Study in SIDIAP, Catalonia, Spain. Clin. Ther. 2025;47(7):484-491. PMID:40348694.

• Fernandez Garcia S, Monfa R, Jimenez CM, Giner Soriano M, Gomez F, Moragas A. Appropriateness of urine culture requests in primary care in Spain: A cross-sectional descriptive study. Aten. Prim. 2025;57(7):103208-103208. PMID:39799637.

• Seyedi S, Sottile S, Abedini M, Boffetta P, Violante FS, Lodi V et al. Antibody Kinetics of Immunological Memory in SARS-CoV-2-Vaccinated Healthcare Workers-The ORCHESTRA Project. Vaccines. 2025;13(6):PMID:40573941.

• Montero Alía JJ, Seda Gombau G, Zamora Sánchez MV, Rodríguez Alvarez MD, López Torrent E, Torán Montserrat P. Analysis of the increase in the complexity of care in family medicine. BMC Prim. Care. 2025;26(1):311-311. PMID:41087914.

• Miserachs M, Martinez Bueno C, Castro A, Pallarés Carratalá V, Pijuan Domenech A, Gordon B et al. Adverse Pregnancy Outcomes and Cardiovascular Disease: A Spanish Cohort. Healthcare. 2025;13(7):PMID:40218026.

• Amigó N, Castelblanco E, Julve J, Martínez Micaelo N, Alonso N, Hernández M et al. Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study. Cardiovasc. Diabetol. 2025;24(1):88-88. PMID:39985069.

• Cruz A, Gonçalves AQ, Vázquez Villegas J, Vallejo Godoy S, Álvarez Ossorio R, Requena P et al. Adapting the implementation of clinical practice guidelines for the screening of infectious diseases and female genital mutilation/cutting in migrants in Spain. Int. J. Infect. Dis. 2026;163108259-108259. PMID:41325924.

• Roca Lecumberri A, Fernández Jarabo N, Albero S, Lucas L, Pelegrí J, Albillos B et al. Adaptation and implementation of a psychoeducational intervention to prevent postpartum depression and anxiety disorders in new mothers: study protocol for a randomized controlled clinical trial. Ment. Health Prev. 2025;40.

• Murrin O, Mounier N, Voller B, Tata L, Gallego Moll C, Roso Llorach A et al. A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data. EBioMedicine. 2025;113105584-105584. PMID:39919332.

• Giner Sorian M, Monfa R, Vives R, Fernandez Garcia S, Vallano A, Morros R. [Clinical characteristics and pharmacological treatment of patients with heart failure in a primary health care cohort]. Aten. Prim. 2025;57(7):103205-103205. PMID:39823656.

• Mateo M, García Egea A, Jacques Aviñó C, Puig Barrachina V, Medina Perucha L. "It Meant Changing My Skin": A Photo-Elicitation Study on the Emotional and Social Well-Being of Women During Perimenopause in Barcelona, Spain. Womens Reprod. Health. 2025;13(1):109-129.

• García Egea A, Jacques Aviñó C, Berenguera A, Baroja Benlliure J, Pinzón Sanabria D, Holst AS et al. "If everyone comes together, many things can be changed": A qualitative study on men's perspectives on menstrual health and equity in the Barcelona area (Spain). PLoS One. 2025;20(2):PMID:40014614.

Proceeding Papers

• Sánchez IL, Palomar Cros A, Giuliodori A, Granés L, Roel E, Duarte Salles T. Trends in incidence of primary colorectal cancer in Catalonia, Spain, from 2007 to 2023: A population-based cohort study. Ann. Oncol. 2025;36.

• Pou MA, Reyes C, Martinez Laguna D, Satorra P, Tebe C, Dalbeth N et al. The Young, the Metabolic and the Hypertensive. A Cluster Analysis of Gout Characteristics and Comorbidities. Ann. Rheum. Dis. 2025;841585-1586.

• Colas S, Bonnet H, Fraticelli L, Bignon E, Jové J, Ehrenstein V et al. Studying Paternal Drug Exposures and Offspring Outcomes: Feasibility Assessment of Large European Databases. Pharmacoepidemiol. Drug Saf. 2025;34154-155.

• Colas S, Bonnet H, Fraticelli L, Bignon E, Jové J, Ehrenstein V et al. Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases. Value Health. 2025;28(12).

• Gomez Lumbreras A, Ouchi D, Giner Soriano M, Morros R. Risk of Hemorrhage in Patients on Oral Anticoagulants Due to Pharmacodynamic Drug Interactions: A Case-Crossover Analysis. Pharmacoepidemiol. Drug Saf. 2025;3448-49.

• Zwiers L, van der Velden F, St Laurent S, Esposito DB, Zhu L, Urdaneta V et al. Risk Factors for Myocarditis/Pericarditis following Mrna-1273 Vaccination: Interim Analysis of a VAC4EU Case-Cohort Study. Pharmacoepidemiol. Drug Saf. 2025;34628-629.

• Bennett M, Lozano A, Evangelidou S, Guzmán Molina C, Romaní O, Jacques Aviñó C. Qualitative Study of Structural Inequalities in the Emotional Well-Being of Adolescents and their Families in Catalonia. Gac. Sanit. 2025;39.

• Pinilla AH, Clua Espuny JL, Satue Gracia E, Martin Lujan FM, Gentille Lorente D, Palleja Millan M et al. Proactive atrial fibrillation screening in primary care: assessing the impact of a device-based approach. Eur. Heart J. 2025;46.

• Raventos A, Clavé P, Bascompte C, Bartolomé M, Engel G, Toran P et al. Prevalence and clinical characteristics of fecal incontinence in women from Mataró: A population-based study. Neurogastroenterol. Motil. 2025;37.

• Margulis AV, de Luise C, Aguado J, Navarro C, Boric K, Campbell C et al. Preliminary Results from a European Post-Authorization Study to Assess the Safety of Paxlovid in Pregnancy. Pharmacoepidemiol. Drug Saf. 2025;34545-546.

• Rebordosa C, de Luise C, Aguado J, Bertran S, Boric K, Campbell C et al. Preliminary Results from a European Post Authorization Study to Assess the Safety of Paxlovid among Patients with Moderate or Severe Hepatic or Renal Impairment. Pharmacoepidemiol. Drug Saf. 2025;34302-303.

• Barrufet C, Berenguera A, Castells X, Sala M, Pardo M, Okan Y et al. Perceptions of Colorectal Cancer Risk: A Qualitative Study in the Target Population for Screening. Gac. Sanit. 2025;39.

• Convertino I, Bissacco CA, Esteban Cledera L, Villalobos F. Mpox Vaccination in Catalunya: Insights on Coverage, Demographics, and Breakthrough Cases. Gac. Sanit. 2025;39.

• Sorup S, Rasmussen TB, Fry C, Villalobos F, Zidan M, van Willigen M et al. Monitoring the Safety of mRNA-1273 COVID-19 Vaccine in the General Population: Results of a Regulator-mandated Post-authorisation Safety Study in Denmark, Norway, Spain, and the United Kingdom (EUPAS44273). Pharmacoepidemiol. Drug Saf. 2025;3493-94.

• Ehrenstein V, Zidan M, Fry C, Villalobos F, Buranelli C, Lupattelli A et al. Monitoring safety of Moderna COVID-19 vaccines in pregnancy: A multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated postauthorisation safety study in the VAC4EU network (EUPAS44450). Pharmacoepidemiol. Drug Saf. 2025;34611-612.

• LA Carrasco Ribelles, M Cabrera Bean, A Prats Uribe, S Khalid, C Viol n. Is fine-tuning useful in EHR-based prediction models? A use case on mortality prediction with longitudinal data from Spanish (SIDIAP) and UK (CPRD) populations aged over 65 years. 2025 Ieee 38th International Symposium On Computer-Based Medical Systems, Cbms. 2025;107-. 110.

• Cruz A, Gonçalves AQ, Vázquez Villegas J, Cuxart Graell A, Vallejo Godoy S, Alvarez Ossorio R et al. Individualized screening of infectious diseases and female genital mutilation in the migrant population: Adapting clinical practice guidelines to the primary care context. Eur. J. Public Health. 2025;3